Pherecydes Pharma develops antibacterial treatments based on bacteriophages (phages) to fight bacterial infections and more specifically antibiotic-resistant infections. Phages are natural predators of bacteria and have no activity vis-à-vis eukaryotic cells, including human cells.
Pherecydes Pharma introduced the concept of precision phage therapy: each treatment composition is chosen after the evaluation of the activity of preselected phages on the specific bacterial strain responsible for the infection. Hence, treatments are individualized.
Pherecydes Pharm is focusing its R&D efforts on 3 targets: Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. These bacteria were selected by the WHO in 2017 as Priority Pathogens.
Some phages developed by Pherecydes Pharma have already been administered to patients as compassionate treatments.
Pherecydes Pharma was founded in 2008. It has two sites: The R&D center is based in Romainville, near Paris, and a cGMP manufacturing facility is under construction in Nantes. Pherecydes Pharma employs a team of more than 20 people.
Pherecydes Pharma’ investors include ACE Management, BMS Systems, Auriga Partners, Go Capital, Cap Decisif, Fa Dièse, Omnes Capital and Business Angels. Pherecydes Pharma has received financial support from the EU, Nantes Métropole, DGA and Bpifrance.